La catena delle opzioni mostra i dati chiave delle opzioni azionarie di Ascent Industries a vari prezzi di esercizio e date di scadenza. I trader utilizzano queste informazioni per analizzare potenziali operazioni e valutare il sentiment del mercato per Ascent Industries..

Ascent Industries (NASDAQ:ACNT) Azioni, Catena delle Opzioni

Ascent Industries

Ascent Industries Co is engaged in the chemical and metal industry. The group operates into two reportable segments namely the Specialty Chemicals and Tubular Products. The Tubular Products segment serves markets through pipe and tube and customers in the appliance, architectural, automotive, and commercial transportation, brewery, chemical, petrochemical, and other industries. The Specialty Chemicals segment produces specialty products for pulp and paper, coatings, adhesives, sealants, and elastomers (CASE), textile, automotive, household, and other industries. It manufactures welded pipe and tube, majorly from stainless steel, duplex, and nickel alloys. The company also produces specialty chemicals and dyes used in various end markets.

Wall Street Bull

Long Ideas

News

Pre-Market Outlook

Markets

Trading Ideas

ACNT

Le valutazioni estreme aprono scenari inaspettati, mentre alcuni titoli ipervenduti mostrano segnali di possibile ripresa.

Titoli ipervenduti: quali aziende potrebbero sorprendere il mercato?

TROX

Scopri i 3 titoli del settore materiali con RSI basso che potrebbero offrire opportunità di acquisto oggi.

3 titoli del settore dei materiali da tenere d&#39;occhio oggi

Ascent Industries Co

Guggenheim analyst Ronald Jewsikow reiterates Tesla (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) with a Sell and maintains $175 price target.

Price Target

Reiteration

Analyst Ratings

TSLA

Guggenheim Reiterates Sell on Tesla, Maintains $175 Price Target

Keefe, Bruyette &amp; Woods analyst Sanjay Sakhrani initiates coverage on Chime Financial (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CHYM#NASDAQ">CHYM</a>) with a Outperform rating and announces Price Target of $42.

Initiation

CHYM

Keefe, Bruyette & Woods Initiates Coverage On Chime Financial with Outperform Rating, Announces Price Target of $42

Guggenheim analyst Michael Schmidt reiterates Cogent Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COGT#NASDAQ">COGT</a>) with a Buy and maintains $17 price target.

COGT

Guggenheim Reiterates Buy on Cogent Biosciences, Maintains $17 Price Target

Guggenheim analyst John Heinbockel reiterates Sysco (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SYY#NYSE">SYY</a>) with a Buy and maintains $82 price target.

Guggenheim Reiterates Buy on Sysco, Maintains $82 Price Target

Guggenheim analyst John Difucci reiterates ServiceNow (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NOW#NYSE">NOW</a>) with a Sell and maintains $724 price target.

Guggenheim Reiterates Sell on ServiceNow, Maintains $724 Price Target

UBS analyst Robin Farley maintains Wynn Resorts (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WYNN#NASDAQ">WYNN</a>) with a Neutral and raises the price target from $83 to $101.

WYNN

UBS Maintains Neutral on Wynn Resorts, Raises Price Target to $101

UBS analyst John Hodulik maintains Warner Bros. Discovery (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WBD#NASDAQ">WBD</a>) with a Neutral and raises the price target from $9 to $10.

UBS Maintains Neutral on Warner Bros. Discovery, Raises Price Target to $10

Wall Street may already be sitting near record highs, but Goldman Sachs believes the rally still has legs—thanks to lower yields, mega-cap momentum and the Fed's return to cutting rates, the bank now sees the S&amp;P 500 hitting <a href="https://www.benzinga.com/topic/expert-ideas">6,900 in the next 12 months.</a>
In a new note Monday, David J. Kostin, chief U.S. equity strategist at Goldman Sachs, said he expects the S&amp;P 500 – as tracked by the Vanguard S&amp;P 500 ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VOO#NYSE">VOO</a>) – to climb to 6,400 in three months, a gain of 3%, 6,600 by year-end, up 6%, and 6,900 within 12 months, an 11% increase.
That's a significant boost from their previous targets of 5,900, 6,100 and 6,500, respectively—and well above the median consensus forecast of 5,975.
<h3 class="wp-block-heading">Why The Upgrade? Think Fed Cuts And Big Tech</h3>
Goldman's forecast shift is built on three key assumptions: earlier and deeper Fed cuts, lower bond yields and the staying power of mega-cap earnings.
The bank now expects the Federal Reserve to cut rates three times within one year, starting in September, followed by two more in 2026. Their rates team sees the 10-year Treasury yield ending 2025 at 4.2%, down from a prior estimate of 4.5%.
According to Goldman, "every 50 basis point decline in real yields is associated with a roughly 3% increase" in the S&amp;P 500's forward price-to-earnings ratio.
Strong first-quarter results from mega-cap names also gave Goldman more confidence that tech leaders can "sustain current investor expectations for their long-term growth."
<h2 class="wp-block-heading">Market Breadth Still Narrow, But That May Change</h2>
Despite the record highs, most stocks still lag behind. 
Goldman said the "median constituent remains more than 10 percent below its 52-week high," pointing to extremely narrow market breadth.
The Invesco S&amp;P 500 Equal-Weight ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RSP#NYSE">RSP</a>) still trades 3% below its record highs hit in late November 2024. 
But rather than a correction, Goldman sees a potential shift in leadership. "We believe a ‘catch up' is more likely than a ‘catch down'" as laggards start to recover in the coming months.
Notably, the recent rally has been unusually sharp: since the April low, the S&amp;P 500 is up 25%, ranking above the 99th percentile of three-month returns in the past 50 years.
<h3 class="wp-block-heading">Earnings Steady For Now, But Tariffs Cloud Outlook</h3>
Goldman is sticking with its earnings growth forecasts of 7% for both 2025 and 2026. Still, Kostin indicated uncertainty tied to the evolving tariff landscape, which could pressure margins.
"The shifting tariff landscape creates large uncertainty around our earnings forecasts," he said, though large-cap firms appear buffered by inventory and cost strategies.
<h3 class="wp-block-heading">3 Investment Plays for the Second Half of 2025</h3>
Goldman is positioning for a rally that broadens beyond mega-caps. The firm outlined three key trade ideas:
<ol class="wp-block-list">
<li>Balanced sector exposure, with overweights in Software &amp; Services, Materials, Utilities, Media &amp; Entertainment and Real Estate.</li>
<li>Alternative asset managers, which lagged despite recovering capital markets.</li>
<li>Companies with high floating-rate debt, which should benefit from lower rates.</li>
</ol>
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/news/25/07/46280221/vice-stocks-beat-esg-trump-2025">Guns, Booze, And Gambling Stocks Are Crushing ESG In Trump&#8217;s America </a></li>
</ul>
Image created using artificial intelligence via Midjourney.

Analyst Color

Large Cap

Macro Economic Events

Broad U.S. Equity ETFs

Econ #s

Economics

ETFs

Rydex ETF Trust Rydex S&P Equal Weight ETF

S&P 500 Near 7,000? Inside Goldman's New Gravity-Defying Forecast

Deutsche Bank analyst Scott Deuschle upgrades General Dynamics (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GD#NYSE">GD</a>) from Hold to Buy and raises the price target from $298 to $342.

Upgrades

Deutsche Bank Upgrades General Dynamics to Buy, Raises Price Target to $342

UBS analyst Manav Gupta maintains Valero Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VLO#NYSE">VLO</a>) with a Buy and raises the price target from $150 to $164.

UBS Maintains Buy on Valero Energy, Raises Price Target to $164

UBS analyst Alex Kramm maintains S&amp;P Global (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPGI#NYSE">SPGI</a>) with a Buy and raises the price target from $575 to $620.

SPGI

UBS Maintains Buy on S&P Global, Raises Price Target to $620

UBS analyst Batya Levi maintains SBA Communications (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SBAC#NASDAQ">SBAC</a>) with a Buy and raises the price target from $280 to $285.

SBAC

UBS Maintains Buy on SBA Communications, Raises Price Target to $285

Guggenheim analyst Gregory Francfort maintains Portillos (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTLO#NASDAQ">PTLO</a>) with a Buy and lowers the price target from $18 to $17.

PTLO

Guggenheim Maintains Buy on Portillos, Lowers Price Target to $17

UBS analyst Brent Dilts maintains Prologis (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PLD#NYSE">PLD</a>) with a Buy and raises the price target from $106 to $120.

UBS Maintains Buy on Prologis, Raises Price Target to $120

Deutsche Bank analyst Scott Deuschle downgrades Northrop Grumman (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NOC#NYSE">NOC</a>) from Buy to Hold and lowers the price target from $580 to $542.

Downgrades

Deutsche Bank Downgrades Northrop Grumman to Hold, Lowers Price Target to $542

UBS analyst Alex Kramm maintains MSCI (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MSCI#NYSE">MSCI</a>) with a Buy and raises the price target from $655 to $700.

MSCI

UBS Maintains Buy on MSCI, Raises Price Target to $700

Guggenheim analyst Howard Ma downgrades Datadog (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DDOG#NASDAQ">DDOG</a>) from Neutral to Sell and announces $105 price target.

DDOG

Guggenheim Downgrades Datadog to Sell, Announces $105 Price Target

Deutsche Bank analyst Scott Deuschle downgrades BWX Technologies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BWXT#NYSE">BWXT</a>) from Buy to Hold and raises the price target from $119 to $150.

BWXT

Deutsche Bank Downgrades BWX Technologies to Hold, Raises Price Target to $150

Rallybio Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RLYB#NASDAQ">RLYB</a>) agreed on Tuesday to sell its interest in REV102, an ENPP1 inhibitor in preclinical development for hypophosphatasia (HPP), to joint venture partner Recursion Pharmaceuticals Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RXRX#NASDAQ">RXRX</a>).
The deal consideration of up to $25 million includes an upfront equity payment of $7.5 million and near-term milestones.
With the upfront payment, Rallybio expects its cash runway to extend into mid-2027.
Also Read: <a target="_blank" href="https://www.benzinga.com/25/04/44697139/nano-cap-rallybio-stops-mid-stage-program-for-pediatric-bleeding-disorder-on-disappointing-efficacy-stock-plunges" rel="noreferrer noopener">Rallybio Stock Plunges After Program For Pediatric Bleeding Disorder Disappoints</a>
The REV102 program, which originated from a joint venture between Rallybio and Recursion, focused on discovering and developing novel, orally available small-molecule inhibitors of ENPP1 for treating patients with HPP.
HPP is a rare, inherited metabolic bone disease caused by a deficiency in the enzyme alkaline phosphatase (ALP).
This deficiency disrupts the mineralization of bones and teeth, leading to a range of skeletal and dental abnormalities.
The lead candidate from the joint venture, REV102, entered into IND-enabling <a target="_blank" href="https://www.benzinga.com/pressreleases/25/07/b46292987/rallybio-sells-interest-in-rev102-program-to-recursion-pharmaceuticals" rel="noreferrer noopener">studies in early 2025</a>.
Under the terms of the agreement, Rallybio is eligible to receive certain payments, including $7.5 million in upfront equity, a contingent equity payment of $12.5 million upon the initiation of additional preclinical studies, and a $5 million milestone payment in connection with the initiation of dosing in a Phase 1 clinical study, as defined in the agreement.
Rallybio is also eligible to receive low single-digit royalties on all future net sales by Recursion. In addition, Rallybio may be eligible to receive certain payments in the event of Recursion&#8217;s sale of the REV102 program.
Recursion Pharmaceuticals announced a reduction in personnel and infrastructure to extend <a target="_blank" href="https://www.benzinga.com/trading-ideas/movers/25/06/45864493/recursion-pharmaceuticals-stock-is-up-10-today-whats-happening" rel="noreferrer noopener">its cash runway in June</a>.
The company announced an approximately 20% reduction in its workforce, extending its cash runway into the fourth quarter of 2027.
The Nvidia-backed biotech company expects its cash burn to be below $450 million in 2025 and under $390 million in 2026.
Price Action: At the last check on Tuesday, RLYB stock was up 36.8% at $0.47, and RXRX stock was up 0.81% at $4.97 during the premarket session.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/news/health-care/25/07/46292859/novartis-gets-swiss-approval-for-first-malaria-drug-for-babies" target="_blank" rel="noreferrer noopener">Novartis Gets Swiss Approval For First Malaria Drug For Babies</a></li>
</ul>
Photo: Shutterstock

Biotech

Penny Stocks

Health Care

Movers

General

RLYB

RXRX

Why Is Microcap Rallybio Stock Trading Higher On Tuesday?

Bit Digital (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BTBT#NASDAQ">BTBT</a>) has made a decisive pivot away from Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>), converting its entire treasury to Ethereum and accumulating roughly 100,000 ETH <a href="https://www.benzinga.com/trading-ideas/movers/25/07/46202593/bitmine-bmnr-stock-soars-as-it-pivots-to-ethereum-treasury-appoints-tom-lee-chairman">on its balance sheet.</a>
What Happened: Speaking to CNBC on Monday, CEO Sam Tabar <a href="https://www.youtube.com/watch?v=1zGjJGzm8qM">described </a>Ethereum as "alive," "institutional," and "the only blockchain capable of rewriting the financial system."
"We sold a profitable business—we exited Bitcoin mining," Tabar said. "We took the cash on our balance sheet, sold all our Bitcoin, and did this raise. I actually personally participated in that raise myself with my own savings, and we poured that all into Ethereum."
With $172 million in capital raised and over 417 Bitcoin liquidated, the firm has now fully embraced an Ethereum (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/eth/usd">ETH</a>)-only treasury strategy. 
According to Tabar, this isn't just about asset exposure—it's about investing in a programmable economic engine.
"Ethereum represents that next wave," Tabar said. "We&#8217;re not just buying a coin. We&#8217;re putting our reserves into a protocol that powers trillions of on-chain activity."
Citing Ethereum's dominance in developer activity, smart contract programmability, and real-world asset tokenization, Tabar argued that Ethereum is becoming a new type of corporate treasury asset, akin to gold or bonds, but dynamic. 
"Ethereum is alive. It moves with technological innovation," he said.
Also Read: <a href="https://www.benzinga.com/crypto/cryptocurrency/25/07/46251827/crypto-tax-loopholes-closing-a-look-inside-bitcoin-senator-lummis-new-bill">Crypto Tax Loopholes Closing? A Look Inside &#8216;Bitcoin Senator&#8217; Lummis&#8217; New Bill</a>
Tabar stressed Ethereum's unique ability to capture real economic value through transaction fees, something he claims Bitcoin cannot replicate. 
"Stablecoin volumes, tokenization, all of that flows back to ETH holders. Bitcoin does not participate in that feedback loop."
He also praised Ethereum's position in institutional infrastructure. 
"There is no second best," he said, referencing Robinhood's (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOOD#NASDAQ">HOOD</a>) recent move to tokenize stocks on Ethereum via Arbitrum (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/">ARB</a>). "Eventually Ethereum will eat the financial world. It will be the basic infrastructure layer to transfer value between parties without escrow agents."
Why It Matters: Bit Digital's pivot comes amid a broader revival of institutional interest in Ethereum.
Ether ETFs, once feared to be "zombie funds," saw $40 million in inflows in June, including from BlackRock's iShares Ethereum Trust (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ETHA#NASDAQ">ETHA</a>). 
Tabar attributes the shift to regulatory clarity.
"There's a much more friendly SEC outlook with respect to projects on the Ethereum blockchain," he said, pointing to legislation like the Genius Act and the proposed Clarity Act, which classify Ethereum as a commodity. "Gary Gensler is gone. That has unleashed Ethereum for adoption by institutions."
While ETFs offer passive ETH exposure, Bit Digital's model adds yield through staking. "You can't stake your ETH in an ETF," Tabar said. "We can stake our ETH and generate a real return on our holdings—currently around 3%—and that compounds."
He added, "That's a much more efficient way to access Ethereum's economic upside through a public vehicle like BTBT."
Read Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/crypto/cryptocurrency/25/07/46248538/bitcoin-ethereum-solana-treasury-companies-need-to-manage-market-volatility-franklin-templeton-report-warns">Bitcoin, Ethereum, Solana Treasury Companies Need To Manage Market Volatility, Franklin Templeton Report Warns</a></li>
</ul>
Image: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$ARB

$BTC

$ETH

BTBT

ETHA

HOOD

Bitcoin Miner Bit Digital Dumped All Its BTC For ETH—And Isn't Looking Back

Press Releases

Ascent Industries Co. Announces Sale of Bristol Metals, LLC for $45 Million

Ascent Industries Brings Performance-Driven Oil & Gas Solutions to AFPM 2025

Ascent Industries Co. Announces Successful Completion of Sale of Bristol Metals, LLC

Ascent Industries Co. Announces Multi-Year Specialty Chemicals Contract, Driving Significant EBITDA Growth

Ascent Industries Announces Upcoming Investor Conference Schedule

Ascent Industries Sets First Quarter 2025 Earnings Conference Call for May 12, 2025, at 5:00 p.m. ET

Ascent Industries Reports First Quarter 2025 Results

Ascent Industries Co. to Divest American Stainless Tubing for $16 Million, Marking Final Step in Strategic Portfolio Realignment

Ascent Industries' Transformation Recognized with Russell 2000 Index Inclusion

Ascent Industries Co. Completes Sale of American Stainless Tubing, Finalizing Transformation to Pure-Play Specialty Chemicals Platform

Alpha Metallurgical Resources, Inc. Common Stock

Alpha Metallurgical

Cleveland-Cliffs

Commercial Metals

Carpenter Technology Corporation Common Stock

Carpenter Tech

Friedman Indus

Gerdau

Warrior Met Coal

Luda Technology Group Limited Ordinary Shares

Luda Technology Group

Ramaco Resources, Inc. - Class A Common Stock

Ramaco Resources

Ramaco Resources, Inc. - Class B Common Stock

Mesabi Tr

ArcelorMittal

Metallus

Nucor

POSCO HOLDINGS INC. American Depositary Shares (Each representing 1/4th of a share of Common Stock)

POSCO Holdings

Radius Recycling, Inc. - Class A Common Stock

Radius Recycling

Reliance

Ryerson Holding

Companhia Siderurgica Nacional S.A. Common Stock

Companhia Siderurgica

Steel Dynamics

SunCoke Energy

Ternium S.A. Ternium S.A. American Depositary Shares (each representing ten shares, USD1.00 par value)

Comments

Ascent Industries

Ascent Industries (ACNT) Opzioni

Ascent Industries (NASDAQ:ACNT) Azioni, Catena delle Opzioni

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO